These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 30288314)

  • 1. Antiretroviral therapy and liver disease progression in HIV and hepatitis C co-infected patients: a systematic review and meta-analysis.
    Llewellyn A; Simmonds M; Irving WL; Brunton G; Sowden AJ
    Hepatol Med Policy; 2016; 1():10. PubMed ID: 30288314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kidney and liver organ transplantation in persons with human immunodeficiency virus: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(4):1-56. PubMed ID: 23074407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. More improvement than progression of liver fibrosis following antiretroviral therapy in a longitudinal cohort of HIV-infected patients with or without HBV and HCV co-infections.
    Ding Y; Duan S; Ye R; Yang Y; Yao S; Wang J; Cao D; Liu X; Lu L; Jia M; Wu Z; He N
    J Viral Hepat; 2017 May; 24(5):412-420. PubMed ID: 27925409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C co-infection is associated with an increased risk of incident chronic kidney disease in HIV-infected patients initiating combination antiretroviral therapy.
    Rossi C; Raboud J; Walmsley S; Cooper C; Antoniou T; Burchell AN; Hull M; Chia J; Hogg RS; Moodie EE; Klein MB;
    BMC Infect Dis; 2017 Apr; 17(1):246. PubMed ID: 28376824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of liver fibrosis and associated risk factors in HIV-infected individuals using transient elastography and serum biomarkers.
    Vermehren J; Vermehren A; Mueller A; Carlebach A; Lutz T; Gute P; Knecht G; Sarrazin C; Friedrich-Rust M; Forestier N; Poynard T; Zeuzem S; Herrmann E; Hofmann WP
    BMC Gastroenterol; 2012 Mar; 12():27. PubMed ID: 22453133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination Antiretroviral Therapy Is Associated With Reduction in Liver Fibrosis Scores in HIV-1-Infected Subjects.
    Li Y; Xie J; Han Y; Wang H; Lv W; Guo F; Qiu Z; Li Y; Du S; Song X; Zhu T; Thio CL; Li T
    Medicine (Baltimore); 2016 Feb; 95(5):e2660. PubMed ID: 26844493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human Immunodeficiency Virus/Hepatitis C Virus (HCV) Co-infected Patients With Cirrhosis Are No Longer at Higher Risk for Hepatocellular Carcinoma or End-Stage Liver Disease as Compared to HCV Mono-infected Patients.
    Salmon-Ceron D; Nahon P; Layese R; Bourcier V; Sogni P; Bani-Sadr F; Audureau E; Merchadou L; Dabis F; Wittkop L; Roudot-Thoraval F;
    Hepatology; 2019 Sep; 70(3):939-954. PubMed ID: 30569448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination antiretroviral therapy is associated with reduction in liver fibrosis scores in patients with HIV and HBV co-infection.
    Yang R; Gui X; Ke H; Xiong Y; Gao S
    AIDS Res Ther; 2021 Dec; 18(1):98. PubMed ID: 34924016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
    Hartwell D; Jones J; Baxter L; Shepherd J
    Health Technol Assess; 2011 Apr; 15(17):i-xii, 1-210. PubMed ID: 21473834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibrosis-4 index predicts mortality in HIV/HCV co-infected patients receiving combination antiretroviral therapy in rural China.
    Chen X; Liu X; Tang R; Ye R; Yang Y; Yao S; Wang J; Ding Y; Duan S; He N
    Biosci Trends; 2019 Mar; 13(1):32-39. PubMed ID: 30726798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C virus increases the risk of kidney disease among HIV-positive patients: Systematic review and meta-analysis.
    Fabrizi F; Dixit V; Martin P; Messa P
    J Med Virol; 2016 Mar; 88(3):487-97. PubMed ID: 26271205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis.
    Pembroke T; Deschenes M; Lebouché B; Benmassaoud A; Sewitch M; Ghali P; Wong P; Halme A; Vuille-Lessard E; Pexos C; Klein MB; Sebastiani G
    J Hepatol; 2017 Oct; 67(4):801-808. PubMed ID: 28527666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV?
    Rockstroh JK; Peters L; Grint D; Soriano V; Reiss P; Monforte Ad; Beniowski M; Losso MH; Kirk O; Kupfer B; Mocroft A;
    J Hepatol; 2013 Aug; 59(2):213-20. PubMed ID: 23583272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver decompensation in HIV/Hepatitis B coinfection in the combination antiretroviral therapy era does not seem increased compared to hepatitis B mono-infection.
    Lieveld FI; Smit C; Richter C; van Erpecum KJ; Spanier BWM; Gisolf EH; Vrolijk JM; Siersema PD; Hoepelman AIM; Reiss P; Arends JE
    Liver Int; 2019 Mar; 39(3):470-483. PubMed ID: 30411848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus.
    Mussini C; Lorenzini P; Puoti M; Lichtner M; Lapadula G; Di Giambenedetto S; Antinori A; Madeddu G; Cozzi-Lepri A; d'Arminio Monforte A; De Luca A;
    PLoS One; 2015; 10(12):e0140877. PubMed ID: 26640953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C.
    Macías J; Mira JA; López-Cortés LF; Santos I; Girón-González JA; González-Serrano M; Merino D; Hernández-Quero J; Rivero A; Merchante N; Trastoy M; Carrillo-Gómez R; Arizcorreta-Yarza A; Gómez-Mateos J; Pineda JA
    Antivir Ther; 2006; 11(7):839-46. PubMed ID: 17302246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after 1997.
    van der Helm J; Geskus R; Sabin C; Meyer L; Del Amo J; Chêne G; Dorrucci M; Muga R; Porter K; Prins M;
    Gastroenterology; 2013 Apr; 144(4):751-760.e2. PubMed ID: 23266560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HCV co-infection and markers of liver injury and fibrosis among HIV-positive childbearing women in Ukraine: results from a cohort study.
    Bailey H; Nizova N; Martsynovska V; Volokha A; Malyuta R; Cortina-Borja M; Thorne C;
    BMC Infect Dis; 2016 Dec; 16(1):755. PubMed ID: 27955711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine.
    Macías J; Castellano V; Merchante N; Palacios RB; Mira JA; Sáez C; García-García JA; Lozano F; Gómez-Mateos JM; Pineda JA
    AIDS; 2004 Mar; 18(5):767-74. PubMed ID: 15075511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.